“Nabota,” which is a botulinum toxin product developed by Daewoong Pharmaceutical, is going to start its third clinical trial in China.
Daewoong Pharmaceutical announced on Dec. 31 that it has started a three-phase clinical trial of Nabota in China and conducted a meeting of clinical researchers at the Fullman Skyway Hotel in Shanghai, China, on Dec. 28. It is planning to release its products in China in 2022.
About 60 people, including Lee Chung-bong, the Chinese clinical director and professor at the 9th Shanghai Transportation University Hospital, clinical researchers and hospital officials, attended the meeting. The three-phase progress plan was announced and a question-and-answer session was conducted.
Daewoong Pharmaceutical plans to enter the Chinese market as an indication of its adaptation to improve frown lines. It compares comparators and effects for about 500 people for 16 weeks to prove non-inferiority and safety. Clinical trials will be conducted at 12 institutions, including the 9th hospital of Shanghai Transportation University Hospital, which is famous for its plastic surgery in China.
“China has the largest number of patients in the world, while its market penetration rate is low at around 2 percent, and there are only two officially licensed drugs, making it the most anticipated market for future growth," said Park Sung-soo, head of the Nabota business division at Daewoong Pharmaceutical.
Nabota, meanwhile, won a sales permit from the U.S. Food and Drug Administration (FDA) in February.
